Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06282809
Other study ID # CSP3325
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date January 2026

Study information

Verified date February 2024
Source HistoSonics, Inc.
Contact Zoe Secord
Phone 612-351-0361
Email zoe.secord@histosonics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.


Description:

This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinoma tumors in patients who are diagnosed with unresectable locally advanced (Stage 3) or oligometastatic disease (Stage 4). The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤36-hours post-index procedure. Additionally, subjects will be followed at 7-day, 14-day, 30-day, 60-day, 120-day, and 180-day timepoints.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date January 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is =18 years of age. 2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments. 3. Subject is diagnosed with unresectable pancreatic adenocarcinoma, locally advanced (Stage 3) or oligometastatic disease (Stage 4) confirmed via CT or MR imaging =30 days prior to the index procedure date. NOTE: If Stage 4 disease, there must be =5 metastatic tumors and the tumors are located only in the liver and/or lung. 4. Subject is not a surgical candidate and has received chemotherapy =16 weeks or subject is intolerant of chemotherapy. NOTE: Intolerance is determined after =8 weeks of chemotherapy with imaging demonstrating stable or improved disease. 5. Subject can tolerate general anesthesia. 6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline. 7. Subject meets the following criteria =14 days prior to the planned index procedure date: - Hemoglobin = 9 g/dL, - Neutrophil count >1.0 x 10^9/L, - Platelet >50 x 10^9/L, - Total bilirubin =2.5x Institutional Upper Limit of Normal (IULN), - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) =2.5x IULN, - International Normalized Ratio (INR) value <1.5, - Serum creatinine <2.0mg/dL or an estimated glomerular filtration rate (eGFR) =45mL/min. 8. The targeted pancreatic tumor is 2-4 cm in longest diameter. 9. The planned histotripsy treatment volume is =1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging. 10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System. 11. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas. Exclusion Criteria: 1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period. 2. Subject has had prior pancreatic, bilioenteric, or gastric surgery. 3. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial. 4. Subject has an uncorrectable coagulopathy. 5. Subject has a life expectancy of less than six (6) months. 6. Subject has a biliary or pancreatic stent and/or percutaneous biliary tube. 7. Subject has portal or superior mesenteric vein thrombosis. 8. Subject has ascites. 9. Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum). 10. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated. 11. Subject has an active duodenal or gastric ulcer requiring medical management. 12. Subject is undergoing active chemotherapy for any cancer =14 days prior to planned index procedure date. 13. Subject is undergoing active immunotherapy =30 days prior to planned index procedure date. 14. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation). 15. Subject has a planned cancer treatment (e.g., pancreatic surgery, chemotherapy, immunotherapy, etc.) prior to completion of the 30-day follow-up visit. 16. Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency). 17. In the investigator's opinion, histotripsy is not a treatment option for the subject. 18. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol. 19. Subject's tumor is not treatable by the System's working ranges (refer to User Guide).

Study Design


Intervention

Device:
HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.

Locations

Country Name City State
Spain Hospital de la Santa Creu i Sant Pau Barcelona

Sponsors (1)

Lead Sponsor Collaborator
HistoSonics, Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy Index procedure-related complications =30 days post index procedure, graded using Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE). [Clinical Events Committee Adjudicated] 30 days post histotripsy procedure
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study